by Keith L. Carson
Volume 3, Issue 5 (September/October 2004)
Several developing countries, including India and China, have young biopharmaceutical industries that have based much of their growth potential on the production of what are currently known as “biogeneric” products, or “bioequivalent” versions of biologics that have already been licensed in Western countries. With a disdain for foreign patents, an established philosophy of copying Western innovations, and success in generic pharmaceutical manufacturing, this approach appeared to be the logical way to build a biologic manufacturing industry. However, there are numerous problems with this development strategy. First and foremost is the inherent incompatability of the very concepts associated with biogeneric products…
Citation:
Carson KL. Biogenerics in Developing Countries: Biotech Boom or Misguided Development Model? BioProcess J, 2004; 3(5): 27-29.